|
|
|
News For SQNM;HITK;DSCI;HTWR;IMGN;MDAS;CRVL;CCRN;AMED;AEZS From The Last 14 Days Check below for free stories on SQNM;HITK;DSCI;HTWR;IMGN;MDAS;CRVL;CCRN;AMED;AEZS the last two weeks. |
|
|
| June 17, 2013 | | 08:51 EDT |  | HTWR | HeartWare gets conditional approval from FDA to enroll patient cohort in trial
HeartWare announced that the FDA has granted conditional approval to an IDE Supplement that allows HeartWare to commence enrollment in an additional patient cohort for ENDURANCE, the company's pivotal, Destination Therapy clinical study. The primary endpoint of the trial is stroke-free (Modified Rankin Score > 4) survival at two years, defined as alive on the originally implanted device, transplanted or explanted due to patient recovery. Secondary endpoints include adverse events such as bleeding and infection, as well as functional status, hospitalization, assessment of neuro-cognitive function and patient quality of life. The final implant was conducted in May, which will result in the final patient reaching the two-year follow up point in May 2014. | | | June 14, 2013 | | 06:17 EDT | | CRVL | CorVel announces $14M stock repurchase plan
 Subscribe for More Information | | | June 12, 2013 | | 07:25 EDT | | DSCI | Derma Sciences reports positive results from Phase 1 diabetic foot ulcer study
Subscribe for More Information | | | 06:25 EDT |  | SQNM | Sequenom likely to beat estimates in 2013, says Piper Jaffray
Subscribe for More Information | | | June 7, 2013 | | 12:46 EDT |  | DSCI | Derma Sciences to host analyst day
Analyst Day to be held in New York on June 12 at 4:30 pm. Webcast Link | | | June 6, 2013 | | 16:07 EDT | | AEZS | Aeterna Zentaris announces dismissal of class action lawsuit
Aeterna Zentaris announced that the previously disclosed purported class action lawsuit filed against the company and certain of its officers by Faruqi & Faruqi LLP in the United States District Court for the Southern District of New York has been entirely dismissed with prejudice and without leave to amend. No payment was made by any of the Defendants to the plaintiff or his counsel in connection with the lawsuit. The plaintiff has 30 days from the docketing of the final judgment to file a notice of appeal, if he determines to do so. | | | June 5, 2013 | | 08:09 EDT | | MDAS | MedAssets pullback brings attractive entry point, says Lazard Capital
Subscribe for More Information | |
|
|
|
|
|
|
